TYG oncology has successfully manufactured reference material. This was 50% funded by Cancer Research UK. This milestone marks the end of our collaboration with CR-UK and we thank them for their non-dilutive, pre-clinical funding and clinical trial planning. We appreciate their independent and unbiased support for our novel approach for treating pancreatic cancer using active checkpoint control immunotherapy coupled with a proven antigen that neutralizes gastrin hormones.
Dr Geert Mudde will be presenting at the 3rd Annual Advances in Immuno-Oncology Congress (organized by Oxford Global) on 24th of May at the Inmarsat Building, 99 City Road Conference Centre, London
Dr Geert Mudde will be presenting at the 6th European Biopharma Congress 18-19 September, Hyatt Place Amsterdam Airport Amsterdam.
